Many pharma companies talk about the importance of ‘patient centric’ clinical trials and involving patients in trial design – but what does this really mean?
Use of real-world evidence is becoming increasingly common to aid the clinical development process and provide important data for pricing discussions once medicines have been approved.
Failed clinical trials can be fatal for small biotechs that don’t have the backing of big pharma, and even having to alter plans can be prohibitively costly.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.